JENA, Germany - On December 30, 2025, InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company specializing in anti-inflammatory treatments targeting the complement system, released various data analyses from the Phase 3 study for vilobelimab in pyoderma gangrenosum (PG). The study was halted earlier in the year following a recommendation from the Independent Data Monitoring Committee (IDMC) due to lack of efficacy. The analyses presented include the primary intent-to-treat analysis and multiple post-hoc analyses conducted on the 54 patients who were part of the trial at the time it was stopped prematurely.